CLSD
Price
$0.77
Change
-$0.04 (-4.94%)
Updated
Jun 27 closing price
Capitalization
61.39M
50 days until earnings call
JAZZ
Price
$106.90
Change
-$0.61 (-0.57%)
Updated
Jun 27 closing price
Capitalization
6.47B
31 days until earnings call
Interact to see
Advertisement

CLSD vs JAZZ

Header iconCLSD vs JAZZ Comparison
Open Charts CLSD vs JAZZBanner chart's image
Clearside Biomedical
Price$0.77
Change-$0.04 (-4.94%)
Volume$283.05K
Capitalization61.39M
Jazz Pharmaceuticals
Price$106.90
Change-$0.61 (-0.57%)
Volume$871.45K
Capitalization6.47B
CLSD vs JAZZ Comparison Chart in %
Loading...
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLSD vs. JAZZ commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLSD is a Hold and JAZZ is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CLSD: $0.77 vs. JAZZ: $106.90)
Brand notoriety: CLSD and JAZZ are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLSD: 107% vs. JAZZ: 86%
Market capitalization -- CLSD: $61.39M vs. JAZZ: $6.47B
CLSD [@Biotechnology] is valued at $61.39M. JAZZ’s [@Biotechnology] market capitalization is $6.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLSD’s FA Score shows that 0 FA rating(s) are green whileJAZZ’s FA Score has 0 green FA rating(s).

  • CLSD’s FA Score: 0 green, 5 red.
  • JAZZ’s FA Score: 0 green, 5 red.
According to our system of comparison, JAZZ is a better buy in the long-term than CLSD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLSD’s TA Score shows that 3 TA indicator(s) are bullish while JAZZ’s TA Score has 3 bullish TA indicator(s).

  • CLSD’s TA Score: 3 bullish, 5 bearish.
  • JAZZ’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CLSD is a better buy in the short-term than JAZZ.

Price Growth

CLSD (@Biotechnology) experienced а -8.31% price change this week, while JAZZ (@Biotechnology) price change was -0.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CLSD is expected to report earnings on Aug 18, 2025.

JAZZ is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JAZZ($6.47B) has a higher market cap than CLSD($61.4M). JAZZ YTD gains are higher at: -13.195 vs. CLSD (-18.947). JAZZ has higher annual earnings (EBITDA): 1.25B vs. CLSD (-19.77M). JAZZ has more cash in the bank: 2.57B vs. CLSD (13.6M). CLSD has less debt than JAZZ: CLSD (619K) vs JAZZ (5.42B). JAZZ has higher revenues than CLSD: JAZZ (4.07B) vs CLSD (3.76M).
CLSDJAZZCLSD / JAZZ
Capitalization61.4M6.47B1%
EBITDA-19.77M1.25B-2%
Gain YTD-18.947-13.195144%
P/E RatioN/A14.53-
Revenue3.76M4.07B0%
Total Cash13.6M2.57B1%
Total Debt619K5.42B0%
FUNDAMENTALS RATINGS
CLSD vs JAZZ: Fundamental Ratings
CLSD
JAZZ
OUTLOOK RATING
1..100
5364
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10060
PRICE GROWTH RATING
1..100
8376
P/E GROWTH RATING
1..100
7990
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAZZ's Valuation (69) in the Pharmaceuticals Other industry is in the same range as CLSD (90) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew similarly to CLSD’s over the last 12 months.

JAZZ's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew similarly to CLSD’s over the last 12 months.

JAZZ's SMR Rating (60) in the Pharmaceuticals Other industry is somewhat better than the same rating for CLSD (100) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew somewhat faster than CLSD’s over the last 12 months.

JAZZ's Price Growth Rating (76) in the Pharmaceuticals Other industry is in the same range as CLSD (83) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew similarly to CLSD’s over the last 12 months.

CLSD's P/E Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as JAZZ (90) in the Pharmaceuticals Other industry. This means that CLSD’s stock grew similarly to JAZZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLSDJAZZ
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
59%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
62%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
49%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
61%
Advances
ODDS (%)
N/A
Bullish Trend 20 days ago
61%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 17 days ago
55%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
63%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTIYX11.890.08
+0.68%
Russell Inv Multifactor Intl Eq Y
LAMSX23.750.08
+0.34%
Lord Abbett Dividend Growth R4
RLBAX36.170.09
+0.25%
American Funds American Balanced R1
CFIGX14.050.01
+0.07%
Columbia Flexible Capital Income C
MCCRX16.390.01
+0.06%
MassMutual Small Cap Opps R3

CLSD and

Correlation & Price change

A.I.dvisor tells us that CLSD and ACLX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLSD and ACLX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLSD
1D Price
Change %
CLSD100%
-5.06%
ACLX - CLSD
28%
Poorly correlated
+0.90%
INBX - CLSD
28%
Poorly correlated
-2.43%
BOLT - CLSD
27%
Poorly correlated
N/A
ATRA - CLSD
27%
Poorly correlated
N/A
JAZZ - CLSD
26%
Poorly correlated
-0.57%
More

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with TECH. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
-0.57%
TECH - JAZZ
39%
Loosely correlated
-1.82%
FTRE - JAZZ
37%
Loosely correlated
-3.95%
BMRN - JAZZ
36%
Loosely correlated
+1.98%
ROIV - JAZZ
36%
Loosely correlated
-1.81%
EXEL - JAZZ
36%
Loosely correlated
+1.35%
More